Chemours (NYSE:CC) Upgraded by Zacks Research to Hold Rating

Key Points

• Chemours has been upgraded from a "strong sell" to a "hold" rating by Zacks Research, indicating a potential stabilization in investor sentiment toward the stock.
• Despite the upgrade, multiple research firms have lowered their price targets for Chemours, with UBS Group reducing it from $18.00 to $17.00 while still maintaining a "buy" rating.
• The company's recent earnings report showed a revenue increase of 5% year-over-year, with an EPS of $0.58, surpassing analysts' estimates, despite a negative net margin of 7.19%.

Zacks Research upgraded shares of Chemours (NYSE:CC - Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Wednesday, August 27th,Zacks.com reports.

Several other analysts have also issued reports on CC. Barclays cut their price target on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 28th. UBS Group cut their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their price target on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. Morgan Stanley cut their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. Finally, Royal Bank Of Canada increased their target price on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Chemours presently has an average rating of "Moderate Buy" and an average price target of $17.38.

Chemours Price Performance

CC traded down $0.42 during trading on Wednesday, reaching $14.90. The stock had a trading volume of 601,342 shares, compared to its average volume of 3,528,468. The business has a 50-day moving average of $13.51 and a 200-day moving average of $12.79. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. Chemours has a one year low of $9.13 and a one year high of $22.38. The stock has a market cap of $2.23 billion, a PE ratio of -5.33 and a beta of 1.61.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business posted $0.38 earnings per share. The company's revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Chemours will post 2.03 EPS for the current fiscal year.

Chemours Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 15th will be issued a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a yield of 2.3%. Chemours's dividend payout ratio (DPR) is -12.50%.

Insider Buying and Selling

In related news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the acquisition, the chief executive officer directly owned 191,546 shares of the company's stock, valued at approximately $2,310,044.76. This represents a 2.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.34% of the stock is owned by company insiders.

Institutional Trading of Chemours

Institutional investors and hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new stake in Chemours in the first quarter worth about $27,000. UMB Bank n.a. lifted its holdings in Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after buying an additional 948 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Chemours by 170.7% during the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares in the last quarter. MTM Investment Management LLC bought a new position in shares of Chemours during the second quarter valued at approximately $27,000. Finally, SouthState Corp bought a new position in shares of Chemours during the first quarter valued at approximately $34,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.